Scinai Immunotherapeutics Ltd. has reported successful in vivo preclinical study results for its anti-IL-17A/F VHH antibody fragment (NanoAb) as a local intralesional biological treatment for mild to moderate plaque psoriasis. The NanoAb targets the two isoforms of the cytokine IL-17 (A and F) implicated in plaque psoriasis.

Researchers from Igyxos SA presented the preclinical profile of IGX-12, a humanized IgG4 antibody, in both female and male infertility models.

Glycoprotein VI (GPVI) is a platelet collagen receptor involved in platelet activation and an emerging target for treating thrombotic disorders such as ischemic stroke. Data have been presented by University of Würzburg scientists regarding a humanized anti-GPVI Fab antibody, EMA-601, with unprecedented potency in vitro and in vivo.

Pharma Foods International Co. Ltd. (PFI) has announced the achievement of a milestone under its licensing agreement with Mitsubishi Tanabe Pharma Corp. for a new investigational therapeutic antibody for autoimmune diseases.

The heterogenous composition of thrombi limits the efficacy of existing therapies.

Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.

Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.

Alchemab Therapeutics Ltd. has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program.